The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI‐antigen levels, clot lysis time and the risk of venous thrombosis

Thrombin activatable fibrinolysis inhibitor (TAFI) is an important inhibitor of fibrinolysis. High TAFI antigen levels are associated with an increased risk of deep venous thrombosis (DVT). Because TAFI levels are partly determined genetically, we assessed the association between three TAFI gene polymorphisms (−438 G/A, 505 A/G and 1040 C/T), TAFI antigen levels and clot lysis times and the risk of DVT. Carriers of the 505G allele, which is associated with lower TAFI antigen levels than the 505A allele, showed an increased risk of DVT. This indicates that the relationship between TAFI and venous thrombosis is more complex than previously suggested.

• Publication year

  2006

• Venue

  British Journal of Haematology

• Publication date

  2006-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.2006.06117.xPMID 16803573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Roles of protease-activated receptors in a mouse model of endotoxemia.

  2006cited by this paper
• Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis.

  2004cited by this paper
• Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays

  2004influential reference
• Estimation of Multilocus Haplotype Effects Using Weighted Penalised Log‐Likelihood: Analysis of Five Sequence Variations at the Cholesteryl Ester Transfer Protein Gene Locus

  2003cited by this paper
• Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris

  2003cited by this paper
• Thrombin‐activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system

  2003cited by this paper
• Frequency of the TAFI –438 G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism

  2003cited by this paper
• A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels.

  2001cited by this paper
• Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.

  2001cited by this paper
• Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled.

  2001influential reference
• Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.

  2000cited by this paper
• Plasma TAFI Levels Influence the Clot Lysis Time in Healthy Individuals in the Presence of an Intact Intrinsic Pathway of Coagulation

  1998cited by this paper
• TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex*

  1996cited by this paper
• A novel , possibly functional , single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor ( TAFI ) gene is also associated with TAFI levels

  year unknowncited by this paper

• Association of Carboxypeptidase B2 Gene Polymorphisms With Graft Loss in Kidney Transplantation

  2026cites this paper
• Investigating the Role of TAFI Gene G>A rs3742264 Polymorphism in patients with Type 2 Diabetes Mellitus.

  2025cites this paper
• The influence of tissue plasminogen activator, plasminogen activator inhibitor-1, and thrombin activable fibrinolytic inhibitor on the risk of venous thrombosis

  2024cites this paper
• Genomic science of risk prediction for venous thromboembolic disease: convenient clarification or compounding complexity.

  2023cites this paper
• Assessment of fibrinolytic markers in patients with deep vein thrombosis

  2021cites this paper
• Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review

  2021cites this paper
• Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

  2021cites this paper
• Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics

  2021cites this paper
• Thrombin-Activatable Fibrinolysis Inhibitor Polymorphisms and Cerebral Venous Thrombosis in Mexican Mestizo Patients

  2018cites this paper
• Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis

  2017influential citation
• Association between thrombin-activatable fibrinolysis inhibitor gene polymorphisms and venous thrombosis risk: a meta-analysis

  2016cites this paper
• Inherited thrombophilia: a double-edged sword.

  2016cites this paper
• Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.

  2015cites this paper
• Genetics of Venous Thrombosis: update in 2015

  2015cites this paper
• Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study

  2015cites this paper
• Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis inhibitor on the risk of diabetic macrovascular disease

  2015cites this paper
• Haplotypes of TAFI gene and the risk of cerebral venous thrombosis--a case-control study.

  2014cites this paper
• Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects.

  2014cites this paper
• TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation

  2013cites this paper
• Diagnosis of Fibrinolytic Disorders

  2012cites this paper
• Prevalence of thrombosis-related DNA polymorphisms in a healthy Greek population.

  2012cites this paper
• Clot lysis time in platelet-rich plasma: Method assessment, comparison with assays in platelet-free and platelet-poor plasmas, and response to tranexamic acid

  2012cites this paper
• Genetic variation in thrombin-activatable fibrinolysis inhibitor is associated with the risk of diabetic nephropathy

  2012cites this paper
• Budd-Chiari Syndrome and Portal Vein Thrombosis: Etiology and Treatment

  2012cites this paper
• Venous and arterial thrombosis : associations and risk factors

  2012cites this paper
• TAFI gene polymorphisms in patients with cerebral venous thrombosis

  2012cites this paper
• Genotyping in Prothrombotic States: Implications for the Clinician

  2011cites this paper
• Etiology and Assessment of Hypercoagulability with Lessons from Heparin-Induced Thrombocytopenia

  2011cites this paper
• An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis.

  2011cites this paper
• [Thrombin-activated inhibitor of fibrinolysis and efficacy and safety of long-term warfarin treatment in patients with venous thromboembolic complications].

  2011cites this paper
• Mutations et polymorphismes des protéines de l'hémostase prédisposant à la thrombose

  2011cites this paper
• Hypercoagulability and Hypofibrinolysis and Risk of Deep Vein Thrombosis and Splanchnic Vein Thrombosis: Similarities and Differences

  2011cites this paper
• Association between the Thr325Ile polymorphism of the thrombinactivatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study

  2010cites this paper
• Deciphering the molecular basis of venous thromboembolism: where are we and where should we go?

  2010cites this paper
• Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome.

  2010cites this paper
• Fibrinolytic parameters in children with noncatheter thrombosis: a pilot study

  2010cites this paper
• Expression changes and roles of matrix metalloproteinases in a rat model of traumatic deep vein thrombosis.

  2010cites this paper
• Genetic basis of thrombosis

  2010cites this paper
• Hypofibrinolysis as a risk factor for recurrent venous thrombosis; results of the LETS follow‐up study

  2010cites this paper
• Plasminogen Activator Inhibitor-1 (PAI-1) Gene 4G/5G Promoter Polymorphism is Seen in Higher Frequency in the Indian Patients With Deep Vein Thrombosis

  2010cites this paper
• Polymorphisms in the CPB2 gene are maintained by balancing selection and result in haplotype-preferential splicing of exon 7.

  2010cites this paper
• The role of the fibrinolytic system in arterial and venous thrombosis

  2010cites this paper
• The Role of Thrombin-Activatable Fibrinolysis Inhibitor in the Pathophysiology of Hemostasis

  2010cites this paper
• Tumor expression of alternatively spliced tissue factor is a prognostic marker in non‐small cell lung cancer

  2010cites this paper
• The Role of Thrombin-Activatable Fibrinolysis Inhibitor in the Pathophysiology of Hemostasis

  2010cites this paper
• The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study 1

  2009cites this paper
• Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men

  2009cites this paper
• Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss.

  2009cites this paper
• Boy with pseudohypoparathyroidism type 1a caused by GNAS gene mutation (deltaN377), Crouzon‐like craniosynostosis, and severe trauma‐induced bleeding

  2009cites this paper
• Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels

  2008cites this paper
• Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis

  2008cites this paper
• Determinants of plasma levels of von Willebrand factor and coagulation factor VIII

  2008cites this paper
• Association Between the Thr325Ile and Ala147Thr Polymorphisms of the TAFI Gene and the Risk of Venous Thromboembolic Disease

  2008influential citation
• Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis

  2007cites this paper
• Fibrinolysis and the risk of venous and arterial thrombosis

  2007cites this paper
• Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors

  2007cites this paper
• Predictive genetic variants for venous thrombosis: what's new?

  2007cites this paper
• Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.

  2007cites this paper
• Thrombophilia and venous thromboembolism: implications for testing.

  2007cites this paper
• Anomalies constitutionnelles de la coagulation prédisposant à la thrombose

  2007cites this paper
• Kidney gene expression analysis in a rat model of intrauterine growth restriction reveals massive alterations of coagulation genes.

  2007cites this paper
• Plasma coagulation factor levels in venous thrombosis.

  2007cites this paper